Compare VanEck Gold Miners ETF (GDX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Repligen Corporation Common Stock — how do they compare? VanEck Gold Miners ETF trades at $85.04 (market cap $26.33B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: VanEck Gold Miners ETF is far larger — about 2.3× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 77 Days and Repligen Corporation Common Stock for 0 Days on average.
| GDX | RGEN | |
|---|---|---|
Market Cap | $26.33B | $11.31B |
Volume | 31,283,423 | 1,216,919 |
52-Week High | $115.84 | $194.57 |
52-Week Low | $68.28 | $102.87 |
Typical Hold Time | 77 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $87.24, down 1.46% over the past day, with a neutral technical signal and bearish moving averages. Key support is at $87, with resistance at $89. Financial ratios are unavailable, but recent news highlights institutional selling and comparisons between gold miners and physical gold ETFs. The fund's performance is influenced by gold prices and interest rate trends.
Outlook remains mixed amid gold price volatility and rising rates. Opportunities include potential catch-up if gold rallies, but risks involve further institutional outflows and macroeconomic pressure on metals. Investor sentiment is cautious, with technicals suggesting limited near-term momentum.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
